You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Dow
Boehringer Ingelheim
Colorcon
Moodys

Last Updated: March 29, 2020

DrugPatentWatch Database Preview

Litigation Details for Pfizer Inc. v. Ranbaxy Laboratories Limited (D. Del. 2007)


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Pfizer Inc. v. Ranbaxy Laboratories Limited (D. Del. 2007)

Small Molecule Drugs cited in Pfizer Inc. v. Ranbaxy Laboratories Limited
Biologic Drugs cited in Pfizer Inc. v. Ranbaxy Laboratories Limited
The biologic drug covered by the patents cited in this case is   Start Trial .

Details for Pfizer Inc. v. Ranbaxy Laboratories Limited (D. Del. 2007)

Date Filed Document No. Description Snippet Link To Document
2007-03-09 1 Complaint References Cited U.S. PATENT DOCUMENTS 3,983,140 A 9/1976 Endo et al. 4,231,938 A 11/1980 Monaghan et …double patenting over the ‘080 Patent in light of the disclosure of the ‘893 Patent. The ‘893 Patent discloses…double patenting over the ‘080 Patent in light of the disclosure of the ‘893 Patent. The ‘893 Patent discloses…the ‘574 Patent.v U.S. Patent No. 4 572 909 U.S. Patent No. 4,572,909 (“the ‘909 Patent”) lists the…States Letters Patent Nos. 4,681,893 (“the ‘893 patent”) and 6,455,574 (“the ‘574 patent”). A copy of each External link to document
2007-05-03 15 Opening Brief in Support Novartis has sought to put Teva 5,246,937 (“ 937 patent”); 5,840,763 (“ 763 patent”); to the hard choice… 5,246,937, 5,840,763, 5,866,581, 5,916,893, 118AII(L) Patents …5,866,581 (“ 581 patent”); 5,916,893 (“ 893 patent”); massive liability for patent infringement when… the and 6,124,304 (“ 304 patent”). The 937 patent is 937 patent expires or Teva prevails in…judgment that the patent [listed in the Famvir® Orange Book patents or that the patents Orange External link to document
2007-06-14 21 Reply Brief coating of HZ-blocker granules U.S. Patent No. 5,075,114 (the “ 114 patent”), which © 2007 Thomson/West. … at least three patents-the 340 patent, the 5,229,137 patent, and the 5,989,588 patent. (DX BE.) This …114 patent to the Examiner. (DX D; DX L, Paper No. 14 at 118.) The 114 patent, like the 072 patent, reveals…has conclusively determined that the ‘893 patent (and its patent term extension) is not invalid or unenforceable…Defense To The ’893 Patent Ranbaxy did not make an obviousness challenge to the ‘893 patent at trial in the External link to document
2007-06-14 22 Reply Brief obtained U.S. Patent No. 4,924,011 (issued May 8, 1990) (“ '011 patent”) and U.S. Patent Re. No. 34,… the patent office in connection with the ‘Oll patent application and the '277 reissue patent application…required patent information relating to such patent has not been filed; (ii) that such patent has expired…may be sued for patent infringement lf the NDA sponsor or patent owner files a patent infringement suit….‘ The patents listed in Merck's N'DA,4 which are the patents-in-suit, are U.S. Patent Nos. 5, External link to document
2007-03-12 4 Patent/Trademark Report to Commissioner the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 4,681,893; 6,455,574 B1; (els… OF PATENT OR TRADEMARK TRADEMARK NO. OR TRADEMARK 1 4,681,893 …Warner-Lambert Expert LTD. PATENT OR DATE OF PATENT … G Other Pleading PATENT OR DATE OF PATENT …REPORT ON THE TO: Director of the U.S. Patent and Trademark Office FILING External link to document
2008-06-20 65 SO ORDERED including without limitation U.S. patent 6,455,574 (“Caduet Patent”); WHEREAS, defendant/counterclaim…Warner-Lambert Export Limited (“Pfizer”) own U.S. patents covering the manufacture, sale and use of products…litigation relating to the Ranbaxy ANDA and Caduet Patents, and Ranbaxy desires to sell a generic product …claims of infringement by Pfizer under the Caduet Patent; WHEREAS, Pfizer andR anbaxy have entered intoa…granted Ranbaxy certain rights to its portfolio of patents relating to atorvastatin; NOW THEREFORE, Pfizer External link to document
2008-06-24 66 Patent/Trademark Report to Commissioner the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,455,574; (Attachments: # (1… including without limitation U.S. patent 6,455,574 (“Caduet Patent”); WHEREAS, defendant/counterclaim…; HOLDER OF PATENT OR TRADEMARK l 4,681,893 7/2 |/1987 Warner-Lambert Company 2 6,455,574 Bl 9/24/2002…and Stipulated lnjunclion (i'e Pulent NO. 6,455,574) CLERK PETER T. DALLEO, CLERK OF COURT …Pleading DATE OF PATENT OR TRADEMARK PATENT OR TRADEMARK NO. HOLDER OF PATENT OR TRADEMARK External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
McKinsey
Baxter
Johnson and Johnson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.